Skip to content
Clinical Trial Events
19th Clinical Trials on Alzheimer's Disease (CTAD) 2026

Talk

Oral Communications

Thu, Nov 19, 2026 · 9:10–10:10 AM EST Ballroom - 4th floor, Boston Marriott Copley Place

About this session

Oral communications: OC40 Early versus delayed cognitive effects of donanemab and lecanemab in early Alzheimer's disease: 24-month real-world trajectories and drug-specific baseline predictors of response; OC41 CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression; OC42 Understanding intermediate values in two-point thresholds for PET, CSF, and plasma biomarkers across cohorts and p-tau217 assays; OC43 Diagnostic Performance of the Fujirebio Lumipulse Plasma p-tau217 and p-tau217/Aβ42 Assays for Detection of Amyloid Pathology in Cognitively Unimpaired Individuals.

Speakers